Oruka Therapeutics (NASDAQ:ORKA) Stock Rating Lowered by Wall Street Zen

Oruka Therapeutics (NASDAQ:ORKA) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Other research analysts have also recently issued research reports about the stock. BTIG Research reissued a “buy” rating and issued a $56.00 target price on shares of Oruka Therapeutics in a report on Monday, September 29th. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research note on Monday, August 18th. Wedbush restated an “outperform” rating and issued a $40.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Wednesday, October 8th. Finally, Barclays began coverage on Oruka Therapeutics in a research note on Monday, October 13th. They issued an “overweight” rating and a $48.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $41.80.

Oruka Therapeutics Trading Up 3.5%

Shares of Oruka Therapeutics stock opened at $27.48 on Friday. The company has a market cap of $1.14 billion, a PE ratio of -9.78 and a beta of -0.29. The company has a 50 day moving average of $17.59 and a 200-day moving average of $13.61. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.02. Research analysts forecast that Oruka Therapeutics will post -3.41 earnings per share for the current year.

Hedge Funds Weigh In On Oruka Therapeutics

Hedge funds have recently modified their holdings of the business. Braidwell LP grew its stake in shares of Oruka Therapeutics by 37.0% in the first quarter. Braidwell LP now owns 1,572,426 shares of the company’s stock worth $16,133,000 after purchasing an additional 424,750 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Oruka Therapeutics by 40.6% during the 2nd quarter. Franklin Resources Inc. now owns 1,012,968 shares of the company’s stock worth $11,355,000 after buying an additional 292,421 shares during the period. Geode Capital Management LLC grew its position in shares of Oruka Therapeutics by 100.6% in the 2nd quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock valued at $7,932,000 after buying an additional 354,821 shares during the last quarter. Affinity Asset Advisors LLC increased its stake in shares of Oruka Therapeutics by 10.7% in the second quarter. Affinity Asset Advisors LLC now owns 603,479 shares of the company’s stock valued at $6,765,000 after buying an additional 58,117 shares during the period. Finally, Cable Car Capital LP increased its stake in shares of Oruka Therapeutics by 33.3% in the second quarter. Cable Car Capital LP now owns 600,000 shares of the company’s stock valued at $6,726,000 after buying an additional 150,000 shares during the period. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.